QLT Announces First Quarter 2015 Results

VANCOUVER, British Columbia, April 30, 2015 (SATPRNEWS.COM) — QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the first quarter ended March 31, 2015. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.2015 FIRST QUARTER FINANCIAL RESULTSOperating Expenses/IncomeDuring the three months ended March 31, 2015, research and development (“R&D”) expenditures were $2.2 million compared to $4.8 million for the same period in 2014. The $2.6 million (54%) decrease was primarily due to higher costs incurred in 2014 related to certain toxicity studies, the impaired dark adaptation study and trailing costs from the Leber Congenital Amaurosis (“LCA”) and Retinitis Pigmentosa (“RP”) Phase Ib retreatment study, which was substantially completed in 2013.During the three months ended March 31, 2015, selling, general and administrative (“SG&A”), expenditures were $3.6 million compared to $2.2 million for the same period in 2014. The $1.4 million (64%) increase in SG&A expenses was primarily due to higher consulting and advisory fees of $1.9 million incurred in connection with the Company’s current exploration and review of strategic alternatives. During the same period in 2014, the Company incurred $0.7 million of consulting and transaction fees related to the exploration and review of strategic alternatives that resulted in the Agreement and Plan of Merger with Auxilium Pharmaceuticals, Inc. (“Auxilium”) dated June 25, 2014 (the “Merger Agreement”), which was subsequently terminated on October 8, 2014.During the three months ended March 31, 2015, the Company recorded nil restructuring charges compared to $0.6 million for the same period in 2014. The 2014 restructuring charges primarily related to severance and termination benefits recorded in connection with the May 31, 2014 departure of our former Senior Vice President of Business Development and Commercial Operations.Other IncomeDuring the three months ended March 31, 2015, the fair value change in contingent consideration was nil compared to the fair value gain of $1.5 million recorded during the same period in 2014. These fair value gains diminished to nil because the final amount of Eligard® related contingent consideration owing to QLT, under the terms of the stock purchase agreement with TOLMAR Holding, Inc. dated October 1, 2009, was collected in August 2014.Operating Loss and Net Loss per ShareThe operating loss for the first quarter of 2015 was $6.0 million, compared to $7.8 million for the same period in 2014. The $1.8 million improvement in operating results was due to the factors described above.Net loss per common share was $0.12 in the first quarter of 2015, compared to $0.13 for the same quarter in 2014. The decrease in loss per share was due to the factors described above.Cash and Cash EquivalentsAs at March 31, 2015, the Company’s consolidated cash and cash equivalents were $151.3 million compared to $155.9 million at December 31, 2014. The $4.6 million decrease was primarily due to cash used in operating activities during the period.  Strategic Review UpdateFollowing the October 8, 2014 termination of the Merger Agreement, QLT has continued to review its strategic alternatives and business options, having engaged Greenhill & Co. to act as its advisor in connection with developing and providing advice with respect to various strategic and business alternatives for the Company. Strategic and business alternatives that QLT may consider include, but are not limited to, asset divestiture, partnering or other collaboration agreements, merger, reverse merger, reorganization or similar transactions, potential acquisitions, or recapitalizations.Synthetic Retinoid Program UpdateQLT continues to advance the development of QLT091001, the Company’s synthetic retinoid product candidate, for the treatment of certain inherited retinal diseases toward pivotal trials. Following meetings with the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency (“EMA”), in 2014 the Company amended and finalized its proposed pivotal trial protocol to test the safety and efficacy of QLT091001 in subjects with Inherited Retinal Disease phenotypically diagnosed as LCA or RP caused by RPE65 or LRAT gene mutations (“IRD”). At present, there is no approved therapeutic treatment option for these patients.In an effort to accelerate the commercial availability of QLT091001 as a treatment option, the Company is currently exploring with the EMA the submission of a Marketing Authorization Application (“MAA”) in 2016 for conditional approval of QLT091001 for the treatment of IRD based on existing clinical data.  During the first quarter of 2015, advisory meetings with certain European regulatory authorities were conducted and QLT is continuing discussions with the European regulatory authorities regarding the MAA for conditional approval.  Conditional approval, if granted, would be made subject to specified conditions, including among other things that the Company complete and have favorable safety and efficacy data from additional studies, including one or more pivotal trials of QLT091001 for IRD.Passive Foreign Investment CompanyThe Company believes that it was classified as a Passive Foreign Investment Company (“PFIC”) for 2008 through 2014, and that it may be classified as a PFIC in 2015, which could have adverse tax consequences for U.S. shareholders. Please refer to our 2014 Annual Report on Form 10-K for additional information.About QLTQLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.QLT’s head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company’s products and developments, please visit our web site at www.qltinc.com.Visudyne® is a registered trademark of Novartis AG
Eligard® is a registered trademark of Tolmar Therapeutics, Inc.
Certain statements in this press release constitute “forward-looking statements” of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to statements concerning our review of strategic alternatives and business options; statements concerning our PFIC status; statements concerning the timing and outcome of our evaluation of a potential EMA conditional approval pathway for QLT091001; statements concerning our potential submission of a MAA with the EMA for conditional approval and the potential commencement of one or more pivotal trials for QLT091001; and statements which contain language such as: “assuming,” “prospects,” “goal,” “future,” “projects,” “potential,” “believes,” “expects,” “hopes,” and “outlook.” Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company’s future operating results are uncertain and likely to fluctuate; currency fluctuations; the risk that we may not receive any or as much additional contingent consideration as we might expect under our agreements with respect to the sale of Visudyne® and the punctal plug delivery system technology; the risk that we will be treated as a PFIC in 2015 and future years; the risk that the Company will determine it is not feasible to submit a MAA for conditional approval with the EMA based upon existing clinical data or other reasons and the impact of this outcome on the Company’s potential plans to commence a pivotal trial for QLT091001; the risk that the EMA denies any conditional approval and the MAA we may submit; risks and uncertainties concerning the impact that QLT’s success or failure in pursuing various future strategic initiatives will have on the market price of our securities; risks resulting from the potential loss of key personnel; uncertainties relating to our development plans, timing and results of the clinical development and commercialization of our products and technologies, including pivotal clinical trials; assumptions related to continued enrollment trends, efforts and success, and the associated costs of these programs; outcomes for our clinical trials may not be favorable or may be less favorable than interim/preliminary results and/or previous trials; there may be varying interpretations of data produced by one or more of our clinical trials; risks and uncertainties associated with the safety and effectiveness of our technology; the timing, expense and uncertainty associated with the regulatory approval process for products to advance through development stages; risks and uncertainties related to the scope, validity, and enforceability of our intellectual property rights and the impact of patents and other intellectual property of third parties; and general economic conditions and other factors described in detail in QLT’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.This press release also contains “forward looking information” that constitutes “financial outlooks” within the meaning of applicable Canadian securities laws. This information is provided to give investors general guidance on management’s current expectations of certain factors affecting our business, including our financial results. Given the uncertainties, assumptions and risk factors associated with this type of information, including those described above, investors are cautioned that the information may not be appropriate for other purposes.
Source: Globenewswire Public
QLT Announces First Quarter 2015 Results

Commercial Electronic Flight Bag Market Worth $4.27 Billion by 2020

DALLAS, April 30, 2015 /SATPR.COM/

According to a new market research report “Commercial Electronic Flight Bag Market by Type (Portable EFB and Installed EFB), Component (Hardware: Class 1, Class 2, and Class 3, Software: Type A, Type B, and Type C), and by Geography – Forecast 2015 to 2020“, published by MarketsandMarkets, the commercial Electronic Flight Bag Market forecasted to reach $4.27 Billion by 2020 with a CAGR of 13.41%.

Browse 73 market data Tables and 60 Figures spread through 200 Pages and in-depth TOC on  Commercial Electronic Flight Bag Market.


Early buyers will receive 10% customization on this report. 

Electronic flight bag (EFB) is equipment that provides real-time flight information, which facilitates the cabin crew to perform flight management tasks more efficiently. Pilots need not carry paper-based reference materials comprising navigational charts and operating manual as an EFB would enable them to be carried in an electronic format, which can be updated on a time-to-time basis. EFB can host software applications to automate other functions that were previously conducted by hand.

An EFB typically weighs around 0.5 to 2.2 kg, which is a substantial reduction of weight as compared to the traditional flight bag that weighs around 30 to 40 kg. It enhances safety and reduces pilot workload & cost of operations by performing flight tasks more efficiently. The various applications of EFB aiding the aircraft by providing an array of information include moving maps, airports map, weather information, and performance calculation. The benefits of using an EFB depend on the scale of operation and type of applications used
The Commercial Electronic Flight Bag Market is estimated to be $2.28 Billion in 2015 and is expected to register a CAGR of 13.41%, to reach $4.27 Billion by 2020. The Asia-Pacific region is expected to be the fastest-growing market during the forecast period.

The Commercial Electronic Flight Bag Market is highly competitive, with a significant number of market players. This report studies the growth strategies adopted by these market players. The strategies adopted by players to expand their global presence and increase their market share include partnerships, agreements, collaborations, joint ventures, mergers, acquisitions, and new product launches.

Speak to Analyst @  http://www.marketsandmarkets.com/speaktoanalyst.asp?id=187615160

The key players covered in the report include International Flight Support (IFS), Thales (France), Navtech, Inc. (Canada), Flightman (Ireland), Jeppesen (U.S.), Lufthansa Systems (Germany), Teledyne Controls (U.S.), Ester Line CMC Electronics (U.S.), and Rockwell Collins (U.S.), among others.

Scope of the report 

This report analyzes the global electronic flight bag market based on:

In addition to market sizes and forecasts, this report also provides a detailed analysis of the market and technology trends to gain competitive market intelligence. The impact of drivers and restraints and their impact on this market have been listed to provide an in-depth insight of the market.

Browse Related Reports 

Flight Management System Market by Cockpit Architecture (VLA, WB, NB, and RTA), Hardware (FMC, CDU, and VDU), Maintenance (Line-fit and Retrofit) & by Geography (North America, Asia-Pacific, the Middle East, and Europe) – Forecast Analysis to 2014 – 2020


Autopilot System Market by Platform (Airborne, Land-based, Sea, Subsea), by Component (GPS, Gyros, Actuators, Software), by Application (Commercial, Defense, & Homeland Security), by Geography (North America, Europe, Asia-Pacific, the Middle East, Latin America, & Africa), Do It Yourself Autopilot – Forecasts & Analysis (2014-2020)


About MarketsandMarkets 

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical info graphics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Aerospace & Defence @  http://www.marketsandmarkets.com/Subscription.html

Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/aerospace-defence  

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

Mr. Rohan
North – Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Source: PR NewsWire Aerospace & Defense
Commercial Electronic Flight Bag Market Worth .27 Billion by 2020

Cellular Biomedicine Group Appoints Two New Members to Scientific Advisory Board

PALO ALTO, Calif., April 30, 2015 (SATPRNEWS.COM) — Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced the appointment of Scott J. Antonia, M.D, Ph.D. and Guoping Fan, Ph.D., as members of the newly established Scientific Advisory Board. Dr. Antonia will advise the company on immuno-oncology and Dr. Fan will advise the company on stem cell technology and its applications.“We are extremely delighted at the opportunity to benefit from the experience and knowledge of each of these doctors, which will fortify our Immuno-Oncology and Stem Cell platforms,” said William (Wei) Cao, Chief Executive Officer for the Company. “Dr. Antonia is one of the foremost experts in the field of immuno-oncology and as a principal investigator of multiple high profile immuno-oncology clinical trials, including anti-PD-1 therapy for advanced lung cancer, has made significant strides with gene-modified tumor cell vaccine development. His research and experience in designing immunotherapy studies will no doubt advance our development of combination therapies for cancer, both in China and internationally. Professor Fan, an outstanding stem cell and neuro cell biologist, has made major contributions in the field of neuroscience and the epigenetic mechanisms underlying stem cell regulation, reprogramming, and human diseases. We look forward to Dr. Fan’s research advances in the understanding of how stem cells self-renew and differentiate into specific cell types and leads to therapies for eye and neurodegenerative diseases.”“I look forward to working with Cellular Biomedicine Group in order to help bring to market safe and effective cancer therapeutics for such a large unmet medical need,” said Dr. Antonia.“I am excited to be working with Cellular Biomedicine Group’s dedicated scientific and management team in order to help translate stem cell discoveries into medical applications,” commented Professor Fan.About Dr. Scott AntoniaScott Antonia serves as department chair and program leader, Thoracic Oncology and program leader of the Immunology Program at Moffitt Cancer Center. He is a professor of oncology at the University of South Florida College of Medicine. Dr. Antonia’s research and clinical interests focus on immunotherapy and immunobiology. He has designed and conducted numerous cutting-edge studies with novel immunotherapeutics and has two patents for technology he has developed. Dr. Antonia received both his medical degree and a doctorate in immunology from the University of Connecticut Health Center. He completed an internal medicine residency at Yale University School of Medicine and pursued additional training at Yale through a medical oncology fellowship and post-doctoral fellowship in immunobiology. Dr. Antonia has published over 90 peer-reviewed publications.About Dr. Guoping FanDr. Guoping Fan is a Professor in the Department of Human Genetics, David Geffen School of Medicine at University of Los Angeles (UCLA) and a member in the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. He has been a faculty member at UCLA since 2001. Prior to that, he was a postdoctoral fellow at the Whitehead Institute for Biomedical Institute, where he studies the role of DNA methylation and neurotrophins in neural development. Professor Fan earned his B.S. in Biochemistry at Nanjing University, China and Ph.D. in Neuroscience at Case Western Reserve University. His current research focuses on the actions of DNA methylation and chromatin-remodeling in regulating neural gene expression, neuronal function, and stem cell differentiation and reprogramming. Professor Fan has published more than 80 peer-reviewed publications in journals including Nature, Science, Nature Neuroscience, and Cell Stem Cell.Under Dr. Fan’s leadership his team has demonstrated that DNA cytosine methylation plays a major role in regulating neural stem cell differentiation and adult brain function. Dr. Fan also derives specific nerve and retinal cells from embryotic stem cells for cell therapy of stroke and age-related macular degeneration.About Cellular Biomedicine GroupCellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.comForward-Looking StatementsStatements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064

Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
Source: Globenewswire Public
Cellular Biomedicine Group Appoints Two New Members to Scientific Advisory Board

Chicago-Area Startup Poised To Bring Massage Into The Digital Age

CHICAGO, April 30, 2015 /SATPR.COM/ — Excel Mobile Massage (EMM) is a new company that caters to the busy lifestyles of Chicagoans desiring a massage on their terms. 

“We see a real opportunity in Chicago to create a better massage experience for customers.  People expect technology to make their lives simpler.  Clients want the convenience to book online or on an APP.  They shouldn’t have to fight traffic to relax, so we come to them,” says Karen Ehlers, EMM Co-President. 

Massage demographics have drastically changed in the last decade.  Clients are no longer just women booking spa days.  More men get massages, and people are incorporating massage into their health and wellness plans.  According to the American Massage Therapy Association, last year 54% of adult Americans received a massage for medical or health reasons.  92 percent believe massage is effective in reducing pain.

“Our clients use massage to address a variety of issues: chronic illness, sports injuries, or just to decompress. That’s why our therapists are trained to deliver any kind of massage,” says Scott Sosne, EMM’s Co-President, 25 year Licensed Massage Therapist.

“We’ve eliminated the tedious stressful parts of booking a massage by using digital tools to focus on client convenience,” says Ehlers.  She and Sosne highlight EMM’s service enhancements:

Embrace Technology:  Clients don’t want to fill out a form, and then wait for a call.  EMM sends an email confirmation with receipt immediately after booking, and an opt-in for appointment reminders.

Time Is Money:  EMM’s website, Android and iPhone APPs give clients access to instant booking of appointments, with their choice of therapist.

Tip Included:  After a massage, clients want to stay relaxed, rather than deal with an awkward tip.  EMM includes a 15% gratuity in all of its pricing.

About EMM

Excel Mobile Massage launched in 2015 with a mission to make massage convenient and stress-free for today’s busy, need-it-now clients.  EMM delivers massages in homes and hotels in Chicago and the Western suburbs.  EMM also offers chair massages for parties, sporting events, corporate team-building and appreciation events, and college wellness programs.  EMM’s highly qualified therapists are interviewed, background checked, insured, licensed and certified.  EMM’s Feel Good – Do Good campaign donates one dollar to cancer charities for every massage booked, and EMM offers senior and Veteran discounts.


Source: PrNewsWire All
Chicago-Area Startup Poised To Bring Massage Into The Digital Age

Advaxis Prices $53 Million Public Offering of Common Stock

PRINCETON, N.J., April 30, 2015 (SATPRNEWS.COM)Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced the pricing of its previously announced underwritten public offering of 2,800,000 shares of its common stock at a public offering price of $19.00 per share. Advaxis has also granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of common stock from Advaxis. The gross proceeds to Advaxis from the public offering are expected to be $53.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on May 5, 2015, subject to customary closing conditions. Advaxis intends to use the net proceeds from the public offering to fund its continued research and development initiatives in connection with expanding its product pipeline and for other general corporate purposes.Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering, Guggenheim Securities, LLC is acting as lead manager, and Janney Montgomery Scott LLC, Aegis Capital Corp. and H.C. Wainwright & Co., LLC are acting as co-managers.The securities described above are being offered by Advaxis pursuant to a “shelf” registration statement on Form S-3 (File No. 333-203497) that was declared effective by the Securities and Exchange Commission (SEC) on April 27, 2015. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, Attention: Equity Syndicate Prospectus Department, or by telephone at 877-547-6340, or by email at prospectus_department@jefferies.com or Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847 or by emailing Barclaysprospectus@broadridge.com. Investors may also obtain these documents for no charge by visiting the SEC’s website at www.sec.gov.Before investing in the offering, you should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Advaxis has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about Advaxis and the offering.This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Advaxis, Inc.Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’s ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.Advaxis’s second Lm-LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. (“Merck”), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). The ongoing clinical trial is designed to evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.Advaxis is also developing Lm-LLO immunotherapy ADXS-HER2, to target the HER2 receptor expressing cancers. HER2 is expressed in certain solid-tumor cancers, including osteosarcoma, breast cancer, esophageal, and gastric cancer. ADXS-HER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-HER2 for both human and animal-health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis has licensed ADXS-HER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.Forward-Looking StatementsThis news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’s ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’s proprietary immunotherapy, ADXS-HPV. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO

609.452.9813 ext. 102

Media Contact:
Tiberend Strategic Advisors, Inc.
Amy S. Wheeler

Source: Globenewswire Public
Advaxis Prices Million Public Offering of Common Stock